WOCKPHARMA · NSE
Wockhardt Limited
₹2,184.4
-0.12% (-₹2.6)
Prev. close
₹2,187
Volume
9,25,190
Delivery %
32.9%
As of
20 Nov 2026
Price history
Analyst sentiment
Analysts lean bullish
2 analyst stances · last 90 days · one per analyst
Trackable
1 · 1 bull / 0 neutral / 0 bear
Long-Horizon
none in range
Commentary
1 · 1 bull / 0 neutral / 0 bear
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Recommends buying Wockhardt at ₹1904 with a target of ₹2000 and a stop loss of ₹1880 for intraday trading.” | Vaishali ParekhPrabhudas Lilladher | Wockhardt Ltd | NOT TRIGGERED | |
| “Bullish on Wockhardt, recommending a buy at ₹1886 with a target of ₹1970 and a stop loss at ₹1850 for intraday traders.” | Vaishali ParekhPrabhudas Lilladher | Wockhardt | HIT | |
| “Recommends buying Wockhardt at ₹1,360 with a target of ₹1,450 and a stop loss at ₹1,320 for intraday trading.” | Vaishali ParekhPrabhudas Lilladher | Wockhardt Ltd | MISS | |
| “Bullish on Wockhardt, recommending a buy at ₹1515.6 with a target of ₹1622 and a stop loss at ₹1462, based on its breako…” | Sumeet BagadiaChoice Equity Broking | Wockhardt Ltd | MISS | |
| “Bullish on Wockhardt for a short- to medium-term rally, targeting ₹2,050 and ₹2,100. The stock delivered a clean breakou…” | Mandar BhojaneChoice Broking | Wockhardt Ltd | MISS | |
| “Bullish on Wockhardt for the near term, with target prices of ₹1,930 and ₹1,945. The stock registered a fresh breakout f…” | Vishnu Kant UpadhyayMaster Capital Services | Wockhardt Ltd | MISS | |
| “Recommends buying Wockhardt at ₹1465.3, targeting ₹1560, with a stop loss at ₹1410, based on technical breakout signals …” | Sumeet BagadiaChoice Equity Broking | Wockhardt Ltd | HIT | |
| “Bullish on Wockhardt, recommending a buy at ₹1512.1 with a target of ₹1625 and a stop loss at ₹1460. This is based on a …” | Sumeet BagadiaChoice Equity Broking | Wockhardt Ltd | PENDING |
Market commentary · 1 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Wockhardt, which has seen a breakout from a triangular pattern on the weekly timeframe and is trading above a…” | Article Analysis AnalysisArticle Analysis | Wockhardt Ltd | — |
Fundamentals
About Wockhardt Limited
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine, as well as offers insulin aspart regular and biphasic drug products. Further, the company offers delivery devices for insulin, including DispoPen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Habil Fakhruddin Khorakiwala
Headquarters
Mumbai
Employees
2,564
Website
wockhardt.comExchange
View on NSE ↗Key stats
Market cap
₹30,861.06 Cr
P/E ratio (TTM)
75.3
Dividend yield
0.00%
EPS (TTM)
₹25.22
Beta (1Y · daily vs NIFTY 50)
0.96
Beta (5Y · monthly vs NIFTY 50)
1.51
Shares float
7.97 Cr
EPS · quarter ended Jun 2026
₹6.55
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹2,708.30 Cr | ₹3,230.00 Cr | ₹2,651.00 Cr | ₹2,798.00 Cr | ₹3,012.00 Cr | ₹3,373.00 Cr | |
EBITDA | ₹-73.24 Cr | ₹135.00 Cr | ₹-81.00 Cr | ₹94.00 Cr | ₹455.00 Cr | ₹678.00 Cr |
| ₹686.06 Cr | ₹-244.00 Cr | ₹-559.00 Cr | ₹-463.00 Cr | ₹-47.00 Cr | ₹213.00 Cr | |
Diluted EPS | ₹61.56 | ₹-20.24 | ₹-38.79 | ₹-32.05 | ₹-3.02 | ₹13.1 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹7,683.00 Cr | ₹7,649.00 Cr | ₹8,135.00 Cr | ₹8,615.00 Cr | |
| — | — | ₹2,184.00 Cr | ₹2,356.00 Cr | ₹2,021.00 Cr | ₹2,233.00 Cr | |
Stockholders' equity | — | — | ₹3,354.00 Cr | ₹3,359.00 Cr | ₹4,353.00 Cr | ₹4,940.00 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹-287.32 Cr | ₹413.00 Cr | ₹153.00 Cr | ₹219.00 Cr | ₹-22.00 Cr | ₹390.00 Cr | |
Investing cash flow | ₹1,470.10 Cr | ₹-201.00 Cr | ₹-125.00 Cr | ₹-137.00 Cr | ₹-783.00 Cr | ₹-241.00 Cr |
| ₹-1,170.82 Cr | ₹-71.00 Cr | ₹-315.00 Cr | ₹334.00 Cr | ₹409.00 Cr | ₹-54.00 Cr | |
Capital expenditure | ₹-165.73 Cr | ₹-212.00 Cr | ₹-209.00 Cr | ₹-216.00 Cr | ₹-365.00 Cr | ₹-364.00 Cr |
End cash position | ₹232.25 Cr | ₹370.00 Cr | ₹90.00 Cr | ₹505.00 Cr | ₹112.00 Cr | ₹217.00 Cr |
Debt issued, Debt repaid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21–Mar 22(3Q) | Jun 22 | Sep 22 | Dec 22 | Mar 23 | Jun 23 | Sep 23 | Dec 23 | Mar 24–Mar 24(2Q) | Jun 24–Sep 24(2Q) | Nov 24–Jun 25(4Q) | Sep 25–Jun 26(4Q) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 68.04% | 67.13% | 65.75% | 63.83% | 60.36% | 59.31% | 58.40% | 55.14% | 54.93% | 51.60% | 51.99% | 49.09% | 49.08% |
| Public | 31.96% | 32.87% | 34.25% | 36.17% | 39.64% | 40.69% | 41.60% | 44.86% | 45.07% | 48.40% | 48.01% | 50.91% | 50.92% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Wockhardt Limited | ₹30,578.29 Cr | ₹1,896.5 | 74.7 | 6.19 | 4.3% | 0.45 | +13.8% | +48.0% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Pharma sector stocks today, November 17: Aarti Drugs jumps 1.60%, Wockhardt up 1.43%, Zydus Life rises 0.98%
Business Upturn · 6 days ago
Sun Pharma, Divi’s Lab, Wockhardt: Pharma stocks surge up to 8% during Muhurat Trading session; why did stocks rally today?
Upstox · 14 days ago